Clinical

Articles

Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.

Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma

The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.

Adjuvant Nivolumab Plus Ipilimumab Combo For Late-Stage Melanoma Did Not Meet RFS End Point

Frontline treatment with tebentafusp significantly improved overall survival in patients with metastatic uveal melanoma, according to data from the phase 3 IMCgp100-202 trial.

Tebentafusp Improves OS in Frontline Setting of Metastatic Uveal Melanoma

When compared against nivolumab alone, relatlimab plus nivolumab delayed progression in patients with unresectable stage III and IV untreated melanoma.

LAG-3 Antibody Relatlimab Combined With PD-1 Inhibition Improves PFS in Previously Untreated Melanoma

Adjuvant immunotherapy treatment was associated with a significant survival benefit for patients with stage II melanoma in a study presented at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care.

Adjuvant Immunotherapy Produced Survival Benefit for Patients With High-Risk Stage II Melanoma

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma

During the age of systemic immunotherapy, investigators observed a change in the incidence of second primary cancers after metastatic melanoma that included solid tumor and hematologic malignancies.

Study Identifies Shift in Incidence of Second Primary Cancers in Patients with Metastatic Melanoma

The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.

FDA Grants Orphan Drug Designation to PVSRIPO for Treatment of Advanced Melanoma

The clinical trial of tebentafusp (IMCgp100) versus investigator’s choice in metastatic uveal melanoma met its pre-defined boundaries for statistical significance of the primary end point of overall survival in its first pre-planned interim analysis.

Phase 3 IMCgp100-202 Trial of Tebentafusp Shows Promise for Metastatic Uveal Melanoma

Videos

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Melanoma | Topics